Northland Securities analyst Carl Byrnes maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) today and set a price target of $47.00. The company’s shares closed last Monday at $26.17.
According to TipRanks.com, Byrnes has 0 stars on 0-5 star ranking scale with an average return of -9.7% and a 39.6% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Opiant Pharmaceuticals, and Aridis Pharmaceuticals.
Heron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $45.86.
The company has a one-year high of $29.49 and a one-year low of $15.68. Currently, Heron Therapeutics has an average volume of 1.05M.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HRTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.